Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A recent study by researchers at the University of Oxford and Koç University in Istanbul revealed new epigenetic inhibitors that substantially increase the efficiency of induced pluripotent stem cell (iPSC) generation by overcoming intrinsic somatic cell barriers.

Horizontal portrait of Professor Udo Oppermann

The research published in Nature Chemical Biology can dramatically improve the technology around induced pluripotent stem cells (iPSCs) and their application in medical research.

iPSCs hold therapeutic potential in regenerative medicine and enable personalised drug discovery efforts and understanding the patient-specific basis of disease. They are typically derived by introducing pluripotency-associated genes, or "reprogramming factors", into a given somatic cell type, in what is currently a slow and inefficient process.

We have discovered that newly developed CBP/EP300 bromodomain inhibitors decrease histone lysine acetylation, chromatin accessibility and expression of genes related to somatic cell identity and promote transition to the stem cell state. This result adds important information how to significantly improve the iPSC technology” says Associate Professor Tamer Onder at Koç University.

Professor Udo Oppermann, from the University of Oxford, adds: "This study, supported by the Royal Society under Newton-Katip Celebi Fund grant scheme, is a wonderful example how international teams can effectively collaborate by student and scientist exchanges. We are very grateful for this support and will continue this exciting collaboration to advance stem cell epigenetic studies".

Currently the teams are continuing their collaborative research into further epigenetic factors that facilitate and improve the production and application of iPSCs in medical research.

Similar stories

Afsie Sabokbar wins Lifetime Achievement at Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar wins Lifetime Achievement at 2021 Teaching Excellence Awards.

NDORMS staff recognised in the 2021 Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar, Associate Professor Stephanie Dakin and Graduate Studies Officer Samuel Burnell were all winners in the Teaching Excellence Awards.

Five ways to take action for your bone health

On World Osteoporosis Day, the International Osteoporosis Foundation (IOF), the world’s largest non-governmental organisation in the bone field, urges action for osteoporosis and fracture prevention.

NDORMS researchers awarded funding by The Paget’s Association

Professor Philippa Hulley and Doctor Helen Knowles have been awarded funding by The Paget’s Association for their research on bone cells.

NDORMS researchers awarded NIHR Fellowships

Six researchers from the Botnar Research Centre have been awarded NIHR (National Institute for Health Research) Fellowships.

Oxford-Bristol Myers Squibb Fellowships awarded to NDORMS researchers

Six researchers from the Botnar Research Centre and the Kennedy Institute of Rheumatology at NDORMS have been awarded fellowships as part of the Oxford-Bristol Myers Squibb Fellowship Programme, providing them an opportunity to gain exposure to the field of commercial drug discovery and development.